{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:23:02Z","timestamp":1757618582375,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10549-025-07770-y","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:25:52Z","timestamp":1751891152000},"page":"15-19","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A 40-year-old woman with early-stage triple-negative breast cancer and a retinal lesion"],"prefix":"10.1007","volume":"213","author":[{"given":"Shivahamy","family":"Maheswaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle J.","family":"Medford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz P.","family":"Stryjewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice N.","family":"Thai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A.","family":"Wander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"7770_CR1","volume-title":"Cancer treatment & survivorship facts & figures 2022\u20132024","author":"American Cancer Society","year":"2022","unstructured":"American Cancer Society (2022) Cancer treatment & survivorship facts & figures 2022\u20132024. American Cancer Society, Atlanta"},{"key":"7770_CR2","doi-asserted-by":"publisher","first-page":"1119611","DOI":"10.3389\/fonc.2023.1119611","volume":"13","author":"S-L Cai","year":"2023","unstructured":"Cai S-L et al (2023) Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. Front Oncol 13:1119611. https:\/\/doi.org\/10.3389\/fonc.2023.1119611","journal-title":"Front Oncol"},{"issue":"15 Pt 1","key":"7770_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"issue":"5","key":"7770_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1200\/JOP.2017.023333","volume":"13","author":"RLB Costa","year":"2017","unstructured":"Costa RLB, Gradishar WJ (2017) Triple-negative breast cancer: current practice and future directions. J Oncol Pract 13(5):301\u2013303. https:\/\/doi.org\/10.1200\/JOP.2017.023333","journal-title":"J Oncol Pract"},{"issue":"21","key":"7770_CR5","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.3390\/cancers14215229","volume":"14","author":"M Gion","year":"2022","unstructured":"Gion M et al (2022) Oligometastatic disease: when stage IV breast cancer could be \u201ccured.\u201d Cancers 14(21):5229. https:\/\/doi.org\/10.3390\/cancers14215229","journal-title":"Cancers"},{"issue":"8","key":"7770_CR6","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.21037\/tcr.2020.01.04","volume":"9","author":"M Terao","year":"2020","unstructured":"Terao M, Niikura N (2020) Diagnosis of oligometastasis. Transl Cancer Res 9(8):5032\u20135037. https:\/\/doi.org\/10.21037\/tcr.2020.01.04","journal-title":"Transl Cancer Res"},{"key":"7770_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.breast.2021.06.010","volume":"59","author":"J-L Lacaze","year":"2021","unstructured":"Lacaze J-L et al (2021) Diagnosis, biology and epidemiology of oligometastatic breast cancer. Breast (Edinburgh, Scotland) 59:144\u2013156. https:\/\/doi.org\/10.1016\/j.breast.2021.06.010","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"9","key":"7770_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"2","key":"7770_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/eye.2012.252","volume":"27","author":"VML Cohen","year":"2013","unstructured":"Cohen VML (2013) Ocular metastases. Eye (Lond) 27(2):137\u2013141. https:\/\/doi.org\/10.1038\/eye.2012.252","journal-title":"Eye (Lond)"},{"key":"7770_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/574086","volume":"2015","author":"I Georgalas","year":"2015","unstructured":"Georgalas I et al (2015) Ophthalmic metastasis of breast cancer and ocular side effects from breast cancer treatment and management: mini review. Biomed Res Int 2015:574086. https:\/\/doi.org\/10.1155\/2015\/574086","journal-title":"Biomed Res Int"},{"issue":"2","key":"7770_CR11","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4103\/0301-4738.154380","volume":"63","author":"S Arepalli","year":"2015","unstructured":"Arepalli S et al (2015) Choroidal metastases: origin, features, and therapy. Indian J Ophthalmol 63(2):122\u2013127. https:\/\/doi.org\/10.4103\/0301-4738.154380","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"7770_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41433-022-02015-4","volume":"37","author":"CL Shields","year":"2023","unstructured":"Shields CL, Kalafatis NE, Gad M, Sen M, Laiton A, Silva AMV, Agrawal K, Lally SE, Shields JA (2023) Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and\/or lens capsule. Eye (Lond) 37(5):809\u2013814. https:\/\/doi.org\/10.1038\/s41433-022-02015-4","journal-title":"Eye (Lond)"},{"key":"7770_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0420.2006.00737.x","volume":"85","author":"S Wickremasinghe","year":"2007","unstructured":"Wickremasinghe S, Dansingani KK, Tranos P, Liyanage S, Jones A, Davey C (2007) Ocular presentations of breast cancer. Acta Ophthalmol Scand 85:133\u2013142","journal-title":"Acta Ophthalmol Scand"},{"issue":"4","key":"7770_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31871\/WJIR.8.4.35","volume":"8","author":"S Daoudi","year":"2020","unstructured":"Daoudi S, Touimi SH, Adrif I et al (2020) Ocular metastasis from breast cancer: case report. World J Innov Res 8(4):10\u201312","journal-title":"World J Innov Res"},{"key":"7770_CR15","doi-asserted-by":"publisher","first-page":"175883592311614","DOI":"10.1177\/17588359231161412","volume":"15","author":"F Merloni","year":"2023","unstructured":"Merloni F et al (2023) Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure. Ther Adv Med Oncol 15:17588359231161412. https:\/\/doi.org\/10.1177\/17588359231161412","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"7770_CR16","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.3390\/ijms23126806","volume":"23","author":"M Park","year":"2022","unstructured":"Park M et al (2022) Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci 23(12):6806. https:\/\/doi.org\/10.3390\/ijms23126806","journal-title":"Int J Mol Sci"},{"key":"7770_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166","journal-title":"Radiother Oncol"},{"key":"7770_CR18","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s12094-023-03170-0","volume":"25","author":"AM Burgaleta","year":"2023","unstructured":"Burgaleta AM, Burguete AB, Guti\u00e9rrez LR et al (2023) Local treatment in oligometastasis from breast cancer: an overview. Clin Transl Oncol 25:2861\u20132867. https:\/\/doi.org\/10.1007\/s12094-023-03170-0","journal-title":"Clin Transl Oncol"},{"key":"7770_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00003086-200203000-00029","volume":"396","author":"HR D\u00fcrr","year":"2002","unstructured":"D\u00fcrr HR, M\u00fcller PE, Lenz T, Baur A, Jansson V, Refior HJ (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop Relat Res 396:191\u2013196","journal-title":"Clin Orthop Relat Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07770-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07770-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07770-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:17:27Z","timestamp":1757207847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07770-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7770"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07770-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AJM: AJM has served as an advisor\/consultant for AstraZeneca, Guardant Health, Illumina, Myriad Genetics, Natera, SAGA Diagnostics, Novartis, Edgewood Oncology, and Science for America, outside the submitted work. TPS: TPS reports no conflict of interest with the content of the herein manuscript. Other professional relationships include: Alcon (Consultant), Aldeyra Therapeutics (Consultant, Equity, Patents), Alimera Science (Advisory Board), EyeCool Therapeutics (Consultant, Equity, Patents), Gyroscope Therapeutics (Research Support), Hubble Therapeutics (Consultant, Equity), Mass General Brigham (Patents, Royalties), Roche (Research Support), Orchard Surgical Center (Equity), Pykus Therapeutics (Consultant, Equity, Patents),  Samsara Vision (Research Support), Tallman Eye Associates (Employee) SAW: Consulting\/Advisory Board: Foundation Medicine, Veracyte, Hologic, Eli Lilly, Biovica, Pfizer\/Arvinas, Puma Biotechnology, Novartis, AstraZeneca, Genentech, Regor Therapeutics, Menarini. Education\/Speaking: Eli Lilly, Guardant Health, 2ndMD. Institutional Research Support: Genentech, Eli Lilly, Pfizer\/Arvinas, Nuvation Bio, Regor Therapeutics, Sermonix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}